NECCHI, ANDREA

NECCHI, ANDREA  

DIPARTIMENTO DI SCIENZE MEDICHE (attivo dal 01/01/2000 al 27/04/2012)  

Mostra records
Risultati 1 - 14 di 14 (tempo di esecuzione: 0.004 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees 2020 Jereczek-Fossa B. A.Jones R.Necchi A.Valdagni R. + Article (author) -
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees 2019 Jereczek-Fossa B. A.Jones R.Necchi A.Valdagni R. + Article (author) -
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma 2016 P. PinciroliP. GiannatempoD. RaggiF.G. De BraudA. Necchi + Article (author) -
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 2016 A. NecchiD. RaggiP. GiannatempoG. PelosiF.G. De Braud + Article (author) -
Immunotherapy advances in uro-genital malignancies 2016 D. RaggiE. VerzoniA. NecchiF. de Braud + Article (author) -
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 2015 E. VerzoniA. NecchiP. GiannatempoD. RaggiF. De Braud + Article (author) -
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes 2015 P. GiannatempoE. FarèD. RaggiB. AvuzziF. De BraudA. Necchi + Article (author) -
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 2015 D. RaggiP. GiannatempoE. VerzoniF. De BraudA. Necchi + Article (author) -
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy 2015 A. NecchiP. GiannatempoE. FarèD. RaggiF. De Braud + Article (author) -
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial 2014 A. NecchiP. GiannatempoE. FarèD. RaggiPENNATI, MARZIAE. TogliardiF. De Braud + Article (author) -
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer 2014 A. NecchiP. GiannatempoD. RaggiE. FarèF.G. De Braud + Article (author) -
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 2013 P. GiannatempoD. RaggiE. FaréD. BiasoniA.M. GianniA. Necchi + Article (author) -
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 2013 A. NecchiD. RaggiE. FarèP. GiannatempoA.M. Gianni + Article (author) -
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 2012 A. NecchiP. GiannatempoM. PennatiF. De BraudA.M. Gianni + Article (author) -